anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This project will develop and establish feasibility of an integrated smart speaker and mobile/web application, FamilyNet, designed to help parents utilize best practices in behavioral parent training to create and implement personalized behavior plans for their children. The FamilyNet system will integrate mobile app, smart speaker technology, and website technologies to assist families in creating their behavior plan, and then will track compliance, timelines, incentives, and other details to assist parents in following through and maintaining the behavior change program that they have created. After development, the intervention program will be pilot-tested with 35 families of youth ages 12-15 with challenging behaviors.

Primary parents will complete measures of parenting practices and child behavior prior to using the FamilyNet system, and again after having access to the program for 4-6 weeks. During the intervention period, user information will be tracked. Post-intervention measures will also include primary parents' perceptions of usability and acceptability of and satisfaction with the FamilyNet system. Children and second parents will also complete satisfaction questionnaires at the post- intervention assessment. Data will be analyzed to determine the degree to which families are able to utilize the FamilyNet interface and report finding it helpful.
As above, your chronic GvHD either has not responded to, or is not expected to, respond to standard immunosuppressive treatment for chronic GvHD. These standard treatments are given in relatively low doses over long intervals. Thus, in this study we are testing an alternate strategy, using a more intensive, combined therapy with the PCR combination to determine if it will improve outcomes. PENTOSTATIN, CYCLOPHOSPHAMIDE plus RITUXIMAB ("PCR") are FDA-approved drugs for chemotherapy of certain lymphomas/leukemias, and although each has been used separately to treat patients with chronic GvHD, they have not been approved as immunosuppressant for the treatment of chronic GvHD, either separately or together. We will study the "PCR" combination in 9-17 patients with chronic GvHD who are refractory to, or not expected to respond to standard therapy. Response will be measured by the achievement of a documented complete remission (i.e., full resolution of all symptoms and signs), and thus, a shortening of the total duration of immunosuppressive (anti-chronic GvHD) therapy. This latter effect may reduce overall infections.
OBJECTIVES: I. Determine the safety of serial intradermal vaccinations of HER-2/neu derived peptides with sargramostim (GM-CSF) as an adjuvant in patients with stage III or IV HER-2/neu expressing breast, ovarian, or nonsmall cell lung cancer. II. Determine whether immunity can be elicited with peptides derived from the intracellular domain of the HER-2/neu protein. III. Determine whether immunity can be elicited with peptides derived from the extracellular domain of the HER-2/neu protein. IV. Determine whether cytotoxic T cells specific for the HER-2/neu protein can be elicited in patients with HLA-A2 by immunization with peptides derived from the HER-2/neu protein.

OUTLINE: Patients receive one of three HER-2/neu peptide vaccine formulations that also contain sargramostim (GM-CSF) as the vaccine adjuvant. Each vaccine is studied in 20 patients. A maximum of 3 patients receive a vaccine each month for 6 months to monitor the potential toxicity associated with sequential immunizations. Patients receive a follow-up evaluation 1 month after the last vaccination. Those patients who have an immune response related to the vaccine will continue to have immunologic evaluations performed every 2 months while immune responses can still be detected.

PROJECTED ACCRUAL: 60 patients will be accrued.
The present invention relates to a hazelnut element B, an extracting method and a pharmaceutical use thereof. The hazelnut element belongs to a novel compound and the pharmaceutical use. The Corylus heterophylla Fisch.ex Bess leaf is used as a raw material. Through alcohol extraction, organic solvent extraction, sililca gel column chromatography and recrystallization process, a novel compound is obtained. The chemical name of the novel compound is 1,3-dihydroxy-5,8-dimethoxy-2,4-bis(3-methylbut-2-enyl)-xanthen-9-one. The novel compound is called as hazelnut element B in short. The production rate is more than 0.01%. The hazelnut element B has a broad pharmaceutical use in preparing the medicine for treating hyperlipemia.
NEW MATERIAL:The compound of formula I (A is CH or N; R is aryl or heterocyclic residue which may be substituted with alkylene, elkyl, etc.; X is single bond, polymethylene group, etc.) and its salt. EXAMPLE:6-( 4-tert-butylphenyl )-[1,3,4]thiadiazol[3,2-a][1,2,3]-triazolo[4,5- d]pyr imidin-9(1H)-one. USE:Antiallergic agent especially effective to suppress the isolation of SRS-A participating in the fit of asthma, and developing its activity by oral administration. PREPARATION:For example, the compound of formula II used as a starting compound is dissolved to obtain an acidic solution, and is made to react with a nitrous acid salt under ice cooling or at room temperature for 30min-10hr. The novel compound of formula II can be prepared by reacting the compound of formula III with a malonic acid ester, and reducing the compound of formula VIprepared from the above reaction product via the compounds of formula IVand formula V.
This is a single-center, open-label (all patients involved know the identity of the drug), single-arm, nonrandomized study of ceftobiprole in healthy men and women. The study is conducted in 2 parts: a pilot study and a main study. Each study (i.e. the pilot study and the main study) consists of 3 phases: a pretreatment phase that includes up to a 21-day screening period, an open-label treatment phase (1 day in the pilot study and 2 days in the main study), and a posttreatment phase that included the end of study evaluations and follow-up study visit or telephone contact planned for 1 to 2 weeks after discharge from the study unit. Serial blood and dialysis samples will be collected at specified time points from predose through 24 hours after the start of the infusion for estimation of ceftobiprole and ceftobiprole medocaril concentrations. Additional samples will be collected for measurement of protein binding. The study will include the following evaluations of safety and tolerability: adverse events, clinical laboratory tests (including hematology, serum chemistry, and urinalysis), electrocardiogram (ECG), vital signs, physical examination, serology, pregnancy tests, urine drug screen, and alcohol breath test. In the pilot study, Ceftobiprole will be locally administered via a microdialysis probe at a concentration of approximately 30 µg/mL for 60 minutes. In the main Study, each volunteer will receive ceftobiprole locally via the microdialysis probe. After the washout period determined by the pilot study, each volunteer will receive a single 2-hour i.v. infusion of ceftobiprole.
PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition containing sofalcone and effective for shortening the treatment period of various diseases. SOLUTION: This composition contains sofalcone, scopolia extract and an antacid. The amount of the scopolia extract is 0.01-5 pts.wt. in terms of dry component based on 1 pt.wt. of sofalcone and that of the antacid is selected to keep the pH in the stomach to 3-5. In the case of using sodium bicarbonate and magnesium silicate aluminate as the antacid, the amounts of the components are 50-2,000mg of sodium bicarbonate and 50-1,500mg of magnesium silicate aluminate per dose in the case of administering the agent at a rate of 3 doses a day. The pharmaceutical composition can be administered orally or parenterally in one to several doses a day for adult for the treatment of gastritis. The administration rate of sofalcone is preferably 10-1,000mg/day.  It is preferable from the viewpoint of the treating effect on gastritis to use an agent having quick-acting gastric acid neutralizing action in combination with an agent having sustained gastric acid neutralizing action as the antacid.
The first foot reflexology was applied to the intervention group for 30 min (20 min on the right foot, 10 min on the left foot) on the first postoperative day (24 h after the surgery). On the second postoperative day, 30 min of foot reflexology was applied to the patients who decided to chest tube removal (CTR). After the foot reflexology applied by the researcher, CTR was performed by the doctor within 10 min. Immediately after CTR, the patient's pain and anxiety level during CTR was measured. At the 15th minute after CTR, the pain and anxiety level of the patients was measured, their satisfaction with the reflexology application was measured. Then, the patients were asked to describe the pain and feelings and thoughts during CTR, 1 hr after CTR, pain level was measured, and they were asked to express their feelings and thoughts about the reflexology application.
PURPOSE OF REVIEW: The conventional definition of chronic kidney disease (CKD) primarily relies on the identification of albuminuria or a decline in estimated glomerular filtration rate (eGFR). For many years, a straightforward eGFR threshold of <60 ml/min/1.73 m 2 has been widely adopted as the standard for defining CKD. Nonetheless, this criterion fails to consider the natural aging process of the kidney, and this oversight may affect the accurate diagnosis of kidney disease particularly at the extremes of age.
RECENT FINDINGS: The fixed eGFR threshold of <60 ml/min/1.73 m 2 for defining CKD misses crucial opportunities for risk prevention. Studies have revealed that the eGFR threshold at which the risks for adverse long-term health outcomes such as mortality, cardiovascular events, and kidney failure begin to rise varies substantially by age. Specifically, this threshold is lower for the elderly and higher for young adults. Consequently, this results in the over-diagnosis of kidney disease in the elderly and the under-diagnosis of kidney disease in young adults.
SUMMARY: To address these limitations of the current CKD definition, we discuss a number of proposed age-adapted eGFR criteria and weigh their pros and cons against the current, simple, and universally accepted approach.
Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner. Subjects in this arm will not use any mouth rinse.
PURPOSE: Medical use of l-muscone is provided to be variously used as a heartometer/circulatory system agonist, a brain disease treatment, and a central nervous system agonist instead of musk. CONSTITUTION: The l-muscone is able to be used instead of musk in the manufacture of various kinds of herb medicine. A day's dosage of the l-muscone is 50 micrograms to 10,000 micrograms, and preferably 50 micrograms to 1,000 micrograms. The l-muscone is medicated via an oral administration manner, an intravenous injection manner, and the other possible clinical channel. The l-muscone has many functions such as a blood vessel relaxation function, a blood pressure drop function, a palpitation suppression function, and shows a superior treatment effect to transient cerebral ischemia attack and stroke. Also, the l-muscone has a panting effect, an ultromotivity reduction effect, and a stress suppression effect.
The topical administration of a plasmid encoding a Type I interferon such as interferon alpha1 (IFN-alpha1) to the cornea has potent anti-herpes activity. The expression of the interferon transgene in the corneas of infected individuals is transient and short-lived. The plasmid protected mice from HSV-1-induced encephalitis in a dose- and time-dependent manner when applied to the cornea prior to infection. The method may be used to treat or prevent herpes infections not only in the eye, but also in other portions of the oropharyngeal region, and in other mucous membranes including the genitalia. Patients presenting with acute or reactivated herpes infections are topically treated with DNA encoding a Type I interferon, where the DNA is not designed to integrate into the genome, but is placed under the control of a promoter that will cause expression of the interferon while the DNA persists in the cells that take it up. By limiting viral replication, the treatment reduces the initial spread of virus, and thereby also reduces the establishment of latent infections. The method provides a low-cost, non-invasive treatment for HSV infection that may either be administered by physicians or other health care personnel, or self-administered by patients.
Patients will receive surveillance until recurrence according to current Danish guidelines with liver enzymes, history and clinical evaluation every 3 months for two years and then every 6 months until 36 months. If an increase in liver enzymes is seen or clinical signs of recurrence (e.g. weight loss, abdominal pain or fatigue) patients will have a CT scan of thorax and abdomen. Blood samples (90 ml blood per visit) will be collected at the same time points as blood is drawn for liver enzymes (i.e. every 6 months until 36 months) for later analysis at the end of study of plasma ctDNA and eccDNA. These measurements will serve to enable post-trial comparison of oncological outcomes for the two arms.
FIELD: medicine, microbiology. SUBSTANCE: invention relates to the production of stable vaccine antianthrax preparations of the high quality. Microbic population is passaged through the body of susceptible animal, analyzed culture is sown on an agar medium containing an antianthrax globulin. Medium ensures to detect toxin-forming clones. Clones are detected under the full value control of the most immunologically important determinants pag, lef, cya by method of polymerase chain reaction. Invention ensures to obtain homogeneous and high-immunogenic cultures by indices of toxin formation determinants from heterogeneous cultures of the vaccine strain STI-1 of decreased immunogenicity and to prevent possible increase of dissociation of properties of cultures at frequent resowing under nonselective conditions. EFFECT: improved method of maintenance. 3 tbl, 4 ex
Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
Using a hybrid Type 2 effectiveness-implementation design, this study tests the effectiveness and implementation of an evidence-based parenting intervention for improving parenting and school outcomes in a sample of 4-year-old children enrolled in public prekindergarten (PreK) programs in Maryland. Thirty Title 1 schools across two Maryland school districts (Baltimore City Public Schools n=20; Cecil County Public Schools n=10) will be randomized into experimental (receive the Chicago Parent Program intervention) or control (usual school practice) conditions. The Chicago Parent Program (CPP) is a 12-session group-based parenting intervention designed to strengthen parenting skills and parent engagement in children's learning and improve children's social-emotional and behavioral competence. All schools will participate for 2 years. In the experimental condition, school staff trained in CPP will implement the program in groups of 10-15 parents of PreK students in a virtual group or in-person group format (format order counterbalanced). Parents in the control condition will complete surveys only. Study outcomes for all participants will be evaluated at PreK baseline (T1), 4-5 months post baseline (T2), in the fall of kindergarten (T3), and at the end of kindergarten (T4). Outcomes include children's social-emotional-behavioral competence, parent engagement in early childhood education, and parenting skills; school community cohesion; kindergarten readiness, chronic absence, and retained in kindergarten. Additional evaluation data will be collected in the experimental condition assessing perceived effectiveness, implementation quality, uptake, and cost-effectiveness to understand factors that affect the likelihood the program can be successfully integrated and sustained in urban and rural school settings.
Approximately one in three older adults (aged 65 years and over) experience pain, negatively impacting their quality of life. Opioid analgesics are commonly prescribed to manage pain; however, balancing the benefits and harms of these high-risk analgesics can be challenging for both healthcare professionals and patients. This is particularly true for older adults, as factors such as polypharmacy, age-related physiological changes and cognitive decline may impact upon opioid safety and efficacy. Deprescribing is the patient-centred process of reducing or discontinuing a medication that is no longer appropriate, or where the risks of continuation are deemed to outweigh the anticipated benefits. Opioid deprescribing has been proposed as a mechanism to reduce individual and societal opioid-related harm; however, to date, research has predominantly focused on the general adult population, rather than older adults. This current opinion aims to summarise the existing opioid deprescribing literature, discussing its applicability for older adults. Drawing on a non-systematic review of the literature, it identifies unique challenges and considerations for this population, highlights international initiatives to enhance opioid deprescribing in clinical practice and proposes future directions to advance the field.
For pediatric patients 3 years of age and older, select the appropriate product (MYRBETRIQ or MYRBETRIQ Granules) based on the patient’s weight.

Pediatric Patients weighing less than 35 kg: Use MYRBETRIQ Granules

The recommendedstarting and maximum doses of MYRBETRIQ Granules, administered as extended-release oralsuspensiononce daily [see Dosage and Administration ( 2.6)] , are shown in Table 1. The recommended dosages aredetermined based on patient weight. Evaluate patients periodically for potential dosage adjustment. For administrationinstructions, see Dosage and Administration ( 2.7) . 

Pediatric Patients weighing 35 kg or more: Use MYRBETRIQ or MYRBETRIQ Granules

The recommended starting dosage of MYRBETRIQ is 25 mg orally once daily. If needed, increase to a maximum dosage of MYRBETRIQ 50 mg orally once daily after 4 to 8 weeks. For administration instructions, see Dosage and Administration ( 2.7). 

The recommended starting dosage of MYRBETRIQ Granules is 6 mL (48 mg) orally once daily. If needed, increase to a maximum dosage of MYRBETRIQ Granules 10 mL (80 mg) orally once daily after 4 to 8 weeks. For administration instructions, see Dosage and Administration ( 2.7).
Provided are a brain image analysis method and a system thereof. According to an embodiment of the present invention, the brain image analysis system comprises an analysis environment providing server, at least one user terminal, and a cloud processing server. The analysis environment providing server includes: a communication module for communicating with the user terminal through a communication network; an analysis interface providing module for configuring a brain image analysis interface, and providing the brain image analysis interface for the user terminal through the communication module; and a database for storing data generated during an operation process of the analysis interface providing module. The analysis interface providing module receives patient information and brain image data corresponding to the patient information from the user terminal. Also, an analysis request with respect to the brain image data is received from the user terminal, and an analysis for the brain image data is performed to correspond the analysis request. Also, an analysis result for the brain image data is provided. Therefore, an easily reproducible brain image analysis interface is provided for a user.
ABSTRACT OF THE DISCLOSURE:           N-lower alkyl neoalkanamides (N-lower alkyl trialkyl-acetamides of certain types) of 1 to 4 carbon atoms in the lower alkyl thereof  and of 5 to 14 carbon atoms in the neoalkanoyl (or trialkylacetyl) group, e.g., N-methyl- and N-ethyl neodecan-amides and N-methyl and N-ethyl neotridecanamides, are new compounds, secondary amides  which have insect repellent properties, being especially effective against cockroaches, e.g., the German cockroach.  However, they are also useful as repellents for other insects, including American cockroaches, mosquitoes, flies, fleas, ants, and lice.  Additionally, they may repel arachnids, such as spiders, ticks and mites.  The new neoalkanamides may be synthesized easily, as by reacting a primary lower alkyl amine with a neoalkanoyl halide, e.g. by reacting methyl amine or ethyl amine with neodecanoyl chloride.         The most effective of the described amides for insect repellency are normally liquid and are sufficiently volatile to be detectable in air by insects.  They may be applied directly to surfaces to be treated or they may be incorporated in detergent compositions, such as built laundry deter-gents, floor and wall cleaners, rug cleaners and shampoos, hair shampoos, and liquid and bar soaps, and have been found to be sufficiently substantive to the substrate being washed so as to impart insect repelling properties to it.  They may be dissolved, dispersed or emulsified (emulsions are considered to be special cases of dispersions) in appropriate liquid media and may be applied to surfaces to be made insect repellent, as by spraying, brushing, wiping or other suitable processes, includ-ing "aerosol" spraying from pressurized containers.  They have been found to be of long lasting effectiveness, with significant and measurable insect repellency being obtainable for as long as two weeks after application.  The described N-lower alkyl neoalkanamides are stable during normal uses, relatively low in manufacturing cost, of high substantivities to substrates, economical to use, unobjectionable in odor to humans, and harmless to humans and animals, and to the environment.
Abdominal subcutaneous fat deposition (ASFD) is not only related to meat quality in the pig industry but also to human health in medicine. It is of great value to elucidate the potential molecular mechanisms of ASFD. The present study aims to identify obese-specific biomarkers and key pathways correlated with ASFD in pigs. The ASF-related mRNA expression dataset GSE136754 was retrieved from the Gene Expression Omnibus (GEO) database and systematically analyzed using a comprehensive bioinformatics method. A total of 565 differentially expressed genes (DEGs) were identified between three obese and three lean pigs, and these DEGs were mainly involved in the p53 signaling pathway, MAPK signaling pathway and fatty acid metabolism. A protein-protein interaction (PPI) network, consisting of 540 nodes and 1,065 edges, was constructed, and the top ten genes with the highest degree scores-ABL1, HDAC1, CDC42, HDAC2, MRPS5, MRPS10, MDM2, JUP, RPL7L1 and UQCRFS1-were identified as hub genes in the whole PPI network. Especially HDAC1, MDM2, MRPS10 and RPL7L1 were identified as potential robust obese-specific biomarkers due to their significant differences in single gene expression levels and high ROC area; this was further verified by quantitative real-time PCR (qRT-PCR) on abdominal subcutaneous fat samples from obese-type (Saba) and lean-type (Large White) pigs. Additionally, a mRNA-miRNA-lncRNA ceRNA network consisting of four potential biomarkers, 15 miRNAs and 51 lncRNAs was established, and two targeted lncRNAs with more connections, XIST and NEAT1, were identified as potentially important regulatory factors. The findings of this study may provide novel insights into the molecular mechanism involved in ASFD.